BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed TRAW catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:63f4eabf0952cfdc2a92@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:TRAW P2 readout (est.): This is an Early-stage Clinical Trial to De
 termine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With 
 Mild to Moderate Influenza
DESCRIPTION:This is an Early-stage Clinical Trial to Determine a Safe and E
 ffective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Inf
 luenza\nNCT07371650 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Traws Phar
 ma\, Inc.\nPrimary completion date (ESTIMATED)\; top-line results usually 
 follow later.\nDate precision: month (shown on the first day)\nTicker TRAW
  (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT07371650\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07371650
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
